Literature DB >> 25269834

Mapping dopaminergic deficiencies in the substantia nigra/ventral tegmental area in schizophrenia.

Matthew W Rice1, Rosalinda C Roberts2, Miguel Melendez-Ferro1,2, Emma Perez-Costas3,4.   

Abstract

Previous work from our laboratory showed deficits in tyrosine hydroxylase protein expression within the substantia nigra/ventral tegmental area (SN/VTA) in schizophrenia. However, little is known about the nature and specific location of these deficits within the SN/VTA. The present study had two aims: (1) test if tyrosine hydroxylase deficits could be explained as the result of neuronal loss; (2) assess if deficits in tyrosine hydroxylase are sub-region specific within the SN/VTA, and thus, could affect specific dopaminergic pathways. To achieve these objectives: (1) we obtained estimates of the number of dopaminergic neurons, total number of neurons, and their ratio in matched SN/VTA schizophrenia and control samples; (2) we performed a qualitative assessment in SN/VTA schizophrenia and control matched samples that were processed simultaneously for tyrosine hydroxylase immunohistochemistry. We did not find any significant differences in the total number of neurons, dopaminergic neurons, or their ratio. Our qualitative study of TH expression showed a conspicuous decrease in labeling of neuronal processes and cell bodies within the SN/VTA, which was sub-region specific. Dorsal diencephalic dopaminergic populations of the SN/VTA presented the most conspicuous decrease in TH labeling. These data support the existence of pathway-specific dopaminergic deficits that would affect the dopamine input to the cortex without significant neuronal loss. Interestingly, these findings support earlier reports of decreases in tyrosine hydroxylase labeling in the target areas for this dopaminergic input in the prefrontal and entorhinal cortex. Finally, our findings support that tyrosine hydroxylase deficits could contribute to the hypodopaminergic state observed in cortical areas in schizophrenia.

Entities:  

Keywords:  Immunohistochemistry; Mesocortical; Mesolimbic; Neuropathology; Neuropsychiatric disorders; Tyrosine hydroxylase

Mesh:

Substances:

Year:  2014        PMID: 25269834      PMCID: PMC4504823          DOI: 10.1007/s00429-014-0901-y

Source DB:  PubMed          Journal:  Brain Struct Funct        ISSN: 1863-2653            Impact factor:   3.270


  69 in total

1.  3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists.

Authors:  A CARLSSON; M LINDQVIST; T MAGNUSSON
Journal:  Nature       Date:  1957-11-30       Impact factor: 49.962

2.  Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection.

Authors:  Chee Yeun Chung; Hyemyung Seo; Kai Christian Sonntag; Andrew Brooks; Ling Lin; Ole Isacson
Journal:  Hum Mol Genet       Date:  2005-05-11       Impact factor: 6.150

Review 3.  How to make a mesodiencephalic dopaminergic neuron.

Authors:  Marten P Smidt; J Peter H Burbach
Journal:  Nat Rev Neurosci       Date:  2007-01       Impact factor: 34.870

Review 4.  Dopaminergic control of working memory and its relevance to schizophrenia: a circuit dynamics perspective.

Authors:  S Tanaka
Journal:  Neuroscience       Date:  2005-12-01       Impact factor: 3.590

5.  Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine.

Authors:  E Grünblatt; S Mandel; G Maor; M B Youdim
Journal:  J Neurochem       Date:  2001-07       Impact factor: 5.372

6.  Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism.

Authors:  Michael A Hauser; Yi-Ju Li; Hong Xu; Maher A Noureddine; Yujun S Shao; Steven R Gullans; Clemens R Scherzer; Roderick V Jensen; Adam C McLaurin; Jason R Gibson; Burton L Scott; Rita M Jewett; Judith E Stenger; Donald E Schmechel; Christine M Hulette; Jeffery M Vance
Journal:  Arch Neurol       Date:  2005-06

7.  Distribution of the catecholaminergic neurons in the central nervous system of human embryos and fetuses.

Authors:  C Verney
Journal:  Microsc Res Tech       Date:  1999-07-01       Impact factor: 2.769

Review 8.  Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment.

Authors:  Gary Remington; Ofer Agid; George Foussias
Journal:  Expert Rev Neurother       Date:  2011-04       Impact factor: 4.618

9.  Morphometry of the human substantia nigra in ageing and Parkinson's disease.

Authors:  Gay Rudow; Richard O'Brien; Alena V Savonenko; Susan M Resnick; Alan B Zonderman; Olga Pletnikova; Laura Marsh; Ted M Dawson; Barbara J Crain; Mark J West; Juan C Troncoso
Journal:  Acta Neuropathol       Date:  2008-02-23       Impact factor: 17.088

10.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease.

Authors:  E Hirsch; A M Graybiel; Y A Agid
Journal:  Nature       Date:  1988-07-28       Impact factor: 49.962

View more
  16 in total

1.  Ultrastructural evidence for glutamatergic dysregulation in schizophrenia.

Authors:  Rosalinda C Roberts; Lesley A McCollum; Kirsten E Schoonover; Samuel J Mabry; Joy K Roche; Adrienne C Lahti
Journal:  Schizophr Res       Date:  2020-01-31       Impact factor: 4.939

2.  Nigral Stress-Induced Dopamine Release in Clinical High Risk and Antipsychotic-Naïve Schizophrenia.

Authors:  Huai-Hsuan Tseng; Jeremy J Watts; Michael Kiang; Ivonne Suridjan; Alan A Wilson; Sylvain Houle; Pablo M Rusjan; Romina Mizrahi
Journal:  Schizophr Bull       Date:  2018-04-06       Impact factor: 9.306

3.  Protein Markers of Neurotransmitter Synthesis and Release in Postmortem Schizophrenia Substantia Nigra.

Authors:  Kirsten E Schoonover; Lesley A McCollum; Rosalinda C Roberts
Journal:  Neuropsychopharmacology       Date:  2016-08-23       Impact factor: 7.853

4.  Evidence for altered excitatory and inhibitory tone in the post-mortem substantia nigra in schizophrenia.

Authors:  Samuel J Mabry; Lesley A McCollum; Charlene B Farmer; Emma S Bloom; Rosalinda C Roberts
Journal:  World J Biol Psychiatry       Date:  2019-06-04       Impact factor: 4.132

5.  Unbiased Stereological Estimates of Dopaminergic and GABAergic Neurons in the A10, A9, and A8 Subregions in the Young Male Macaque.

Authors:  Emily A Kelly; Jancy Contreras; Annie Duan; Rochelle Vassell; Julie L Fudge
Journal:  Neuroscience       Date:  2022-06-20       Impact factor: 3.708

Review 6.  Pathway-Specific Dopamine Abnormalities in Schizophrenia.

Authors:  Jodi J Weinstein; Muhammad O Chohan; Mark Slifstein; Lawrence S Kegeles; Holly Moore; Anissa Abi-Dargham
Journal:  Biol Psychiatry       Date:  2016-03-31       Impact factor: 13.382

7.  Reduced Midbrain Dopamine Neuron Number in the Adult Non-human Primate Brain after Fetal Radiation Exposure.

Authors:  Lynn D Selemon; Anita Begovic
Journal:  Neuroscience       Date:  2020-07-11       Impact factor: 3.590

8.  Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain.

Authors:  T D Purves-Tyson; S J Owens; D A Rothmond; G M Halliday; K L Double; J Stevens; T McCrossin; C Shannon Weickert
Journal:  Transl Psychiatry       Date:  2017-01-17       Impact factor: 6.222

Review 9.  Genetic Variations Associated with Sleep Disorders in Patients with Schizophrenia: A Systematic Review.

Authors:  Konstantinos Assimakopoulos; Katerina Karaivazoglou; Maria Skokou; Marina Kalogeropoulou; Panagiotis Kolios; Philippos Gourzis; George P Patrinos; Evangelia Eirini Tsermpini
Journal:  Medicines (Basel)       Date:  2018-03-24

10.  Dopaminergic control of ADAMTS2 expression through cAMP/CREB and ERK: molecular effects of antipsychotics.

Authors:  Fulgencio Ruso-Julve; Ana Pombero; Fuencisla Pilar-Cuéllar; Nuria García-Díaz; Raquel Garcia-Lopez; María Juncal-Ruiz; Elena Castro; Álvaro Díaz; Javier Vazquez-Bourgón; Agustín García-Blanco; Emilio Garro-Martinez; Helena Pisonero; Alicia Estirado; Rosa Ayesa-Arriola; Juan López-Giménez; Federico Mayor; Elsa Valdizán; Javier Meana; Javier Gonzalez-Maeso; Salvador Martínez; José Pedro Vaqué; Benedicto Crespo-Facorro
Journal:  Transl Psychiatry       Date:  2019-11-18       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.